Overview
- Scripps Research reported a structural blood panel targeting folding changes in C1QA, clusterin and apolipoprotein B that classified cognitive status with about 83% accuracy across three groups and above 93% in some two‑group comparisons.
- The Nature Aging study analyzed 520 samples using mass spectrometry and machine learning, showed consistent results in independent cohorts, and tracked changes over time with roughly 86% accuracy on repeat samples.
- Researchers found links between structural accessibility and cognitive scores, explored APOE ε4–related differences, and noted sex‑specific patterns tied to symptom burden, indicating potential biological modifiers of test performance.
- A JAMA Network Open analysis from the Women’s Health Initiative Memory Study found baseline plasma p‑tau217 levels predicted risk of mild cognitive impairment or dementia up to 25 years in older women.
- The p‑tau217 associations varied by age, APOE ε4 status, race and prior hormone therapy, reinforcing that broader, diverse validation and assay standardization are essential before routine screening.